Patient ID : p\_id Name : p\_name Age/Sex : age\_sex
Ref. by : doctor\_ref Lab no : Date : test\_date
QUADRUPLE TEST
Chemiluminescent immunometric assay (CLIA)
Serum
PATIENT SPECIFICATIONS ULTRA SOUND DETAILS
WEIGHT Kg. DATE OF ULTRASOUND
H/O SMOKING METHOD FOR GESTATION
H/O DIABETES FOETUS
H/O IVF GA ON THE DAY OF SAMPLE COLLECTION Wks+Days
ETHNIC ORIGIN
\*Graph enclosed
\*Result relate only to the sample, as received
\*The calculated risk by PRISCA depends on the accuracy of the information provided by the referring physician.
\*All the soft ware may not give similar risk factor for the similar data.
Test name Result Units Reference range
Alpha Feto Protein (Maternal Screen)Serum 64.70 ng/mL Pregnancy:2nd Trimester ( 14+3 to 21+3 )(W+D)
( 27.20 – 139.00 )
Unconjugated Estriol (uE3\*)Serum 2.190 ng/mL Pregnancy , 2nd Trimester
Gest.Week ( 14 -19 ):( 0.14 - 3.02 )
Pregnancy, 3rd Trimester
Gest.Week ( 27 - 39 ):(2.3 – 11.2)
HCG, Quantitative (Maternal Screen)Serum 36856.00 mlU/mL Pregnancy Gest. Week
(14 - 21) : (6140 - 78100)
Inhibin A,Maternal markerSerum (CLIA) 212.40 pg/mL
Interpretation of Inhibin A :
Gestational age in weeks Medians in pg/mL
15 157.55
16 153.29
17 151.20
18 155.14
19 165.18
20 185.76
Clinical Use
Prenatal Risk assessment for down syndrome.
Increased Levels
in down Syndrome pregnancies, Inhibin A levels are two fold higher then in unaffected pregnancies. addition of inhibin A testing to AFB,
beta HCG, and Free Estriol Improves the detection rate by approximately 10%.
Decreased Levels
Menopause
NOTE : This test was processed at third party lab.
.